884 results on '"Woermann B"'
Search Results
202. Autologous Bone Marrow Transplantation in Adult Lymphoblastic Leukaemia — Single Centre Experience
203. Philadelphia (Ph)-Chromosome-Negative Peripheral Blood Stem Cells can be Mobilized in the Early Phase of Recovery after a Myelosuppressive Chemotherapy in Ph-Chromosome-Positive Acute Lymphoblastic Leukemia
204. Cranial Computed Tomographic Scans at Diagnosis in Children with Leukemia
205. Idarubicin and Ifosfamide in the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia
206. Experience with BFM 1990 Protocol Treatment of Recurrent Childhood Lymphoblastic Leukemia. Report of the Polish Children’s Leukemia/Lymphoma Study Group
207. Treatment of High-Risk Acute Lymphoblastic Leukemia. Preliminary Results of the Protocol PETHEMA ALL-93
208. Treatment of Ph+ and t(4;11)+ Acute Lymphoblastic Leukemia in Adults
209. Adoptive Immunotherapy in the Treatment of Post-Transplant Relapse and Epstein-Barr Virus Lymphoproliferative Disorders
210. Cellular Immunotherapy of Cancer: Adoptive Transfer of Monocyte-Derived Tumorcytotoxic Macrophages
211. GM-CSF Stimulation of Immune Response in Minimal Residual Cancer
212. Modulation of Ara-C Metabolism to Improve AML Response
213. Induction of Graft-versus-Leukemia-Activity after Peripheral Blood Progenitor Cell Transplantation (PBPCT)
214. Retinoids Modulate Ara-CTP Pharmacology in the HL-60 Acute Leukemia Cell line
215. Modulation of Ara-C Cytotoxicity by Coadministration with Antisignalling Drugs in HL60 and Ara-C-Resistant HL60/Ara-C Cells
216. Gene Marking to Establish the Biology of Minimal Residual Disease and Relapse
217. Experimental Basis for Immunotherapy of Metastases
218. Gemcitabine-Mediated Enhancement of Cellular Cytarabine-5′-Triphosphate (ara-CTP) Accumulation
219. Induction of Apoptosis in Vitro by ARA-C, VP-16, MITOX, DNR, IDA and FLU in Myeloid Leukemic Cells
220. Primary Resistance to Ara-C in AML Progenitor Cells and its Modulation by Cytokines
221. Cytotoxic Activity and Pharmacology of an Ara-CMP Prodrug in T-leukemic Sublines Resistant to Ara-C
222. Comparison of Hydroxyurea, Fludarabine and Cladribine in Modulating Ara-C Pharmacology in the Ara-C sensitive and resistant HL-60 and HL-60/Ara-C Cell Lines
223. Cellular Metabolism and T-ALL Specificity of Arabinosylguanine: a Review
224. Interaction of 1-β-D-Arabinofuranosylcytosine with Lipid Metabolism
225. High Serum IGFBP-2 in Acute Lymphoblastic Leukemia may be an Indication for Increased Risk of Relapse
226. Thrombopoietin Supports the Continuous Growth of Cytokine-Dependent Human Leukemia Cell Lines
227. Response of AML Blasts to Ara-C: Role of BCL-2 in the Regulation of Drug Sensitivity
228. Shc Overexpression Induces Selective Hypersensitivity to GM-CSF and Prevents Apoptosis of the GM-CSF-Dependent Acute Myelogenous Leukemia Cell Line GF-D8
229. AraC Metabolism in Fresh Leukemic Blasts/ Normal Bone Marrow/ Hematopoetic Stem Cells and its Impact on the Lipid Composition of Leukemic Cells (HL60)
230. In Vitro Monitoring of Asparaginase: Unphysiological Alteration of the Culture Medium
231. Effect of Combined Treatment with 4-Hydroperoxycyclophosphamide and Fludarabine on Cytotoxicity and Repair of Damaged DNA
232. Pharmacokinetics and Metabolism of Low-Dose ATRA in Children — First Observations
233. Enhanced Effects of Adriamycin by Combination with a New Ribonucleotide Reductase Inhibitor,Trimidox, in Murine Leukemia
234. Asparagine Synthetase in Pediatric Acute Leukemias: AML-M5 Subtype Shows Lowest Activity
235. Pharmacokinetic Basis for an Oral Chemotherapy with Idarubicin and Etoposide: Dose-Dependent Biological Effects of Topoisomerase-II-Inhibitors
236. Involvement of ICE-Like Proteases in Gemcitabine-Induced Programmed Cell Death
237. Functional Studies of Daunorubicin Transport in Human Leukemic Cells
238. Drug Resistance Testing of Acute Myelogenous Leukemia in Adults — Initial Results with the MTT Assay
239. Correlation of in Vitro Drug Sensitivity with Clinical Outcome in Adult AML
240. Pharmacokinetics and Pharmacodynamics of Asparaginase
241. Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells
242. Predictive Value of Pretherapeutic In-Vitro Chemosensitivity Testing in Adult AML
243. In Vitro Drug Resistance in Childhood Acute Myeloid Leukemia: a Preliminary Analysis
244. Idarubicin Activity Against Multidrug-Resistant (mdr-1+) Cells is Increased by Cyclosporin A
245. Some Reflections on P-Glycoprotein Expression in Acute Leukemia
246. Zidovudine Induces Resistance to Antineoplastic Agents and Alterations in Apoptosis in T-Cell Lymphoma Cells
247. Treatment of Poor Prognosis Acute Myelogenous Leukemia with PSC-833 and Mitoxantrone, Etoposide, Cytarabine
248. Approaches to Overcome Multidrug Resistance: PSC and CdA/ara-C Combination Chemotherapy
249. In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bcl-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy
250. AML in the Elderly: a Biologically Distinct Disease in which MDR1 Expression and Unfavorable Cytogenetics Contribute to Poor Clinical Response. Studies of the Southwest Oncology Group
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.